Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I’m in the same boat. So frustrating as we are stuck.
I’m really thinking of selling even though so much on the horizon and the market cap is so ridiculous.
These guys just can’t seem to execute. The most troubling part is their lack of transparency.
That’s what they should be doing. If they can’t get the rights to those drugs back voluntarily they should sue for default. Mnk has publicly said its generic operations are discontinued implying it is not putting any more resources into them. At a minimum mnk has a good faith obligations to use best efforts to maximize sales under the contract.
This is not a difficult claim to prove.
Mnk has now classified its entire generic group as discontinued operations.
It would be nice to get a comment from ipci on this.
Why are these guys always hiding the ball. What - do they think the low numbers will tank the stock? Their lack of transparency has already done that.
Has discovery started in the suit? I would be interested to know what was known and not disclosed on the andas.
This company is just way too secretive. Considering where we are at with the price you would think they would be trying a new approach.
I agree. It would be an absolute disaster and incredibly stupid. But this company has done many boneheaded things. Why can’t they just come out and say we will reduce expenses to meet income.
Mc is price times outstanding shares. Increase outstanding shares you increase market cap.
That is why the mc went up at the last offering.
Does anyone recall what the seroquel rev was for the quarter
Hope not. But he has done a lot of things that I would have never imagined
Can’t believe they sit at this cash level
40 m shares at.6 reverse split 10 to 1. Now 4 mil shares at 6.00. Issue 3 mil more shares. You have a 42m mc.
Not sure why you say that. A reverse split and an offering will get us above 1.00 and 35m. It will also practically wipe us out.
It is the worst case scenario for us.
Agree with that thought. I don’t think the company gets it
Patients comment to impact that the sp is clearly undervalued bc nothing has changed since the sp was at 2.00 or whatever indicates he doesn’t get it. The reason the sp keeps dropping is bc nothing has changed. The company is bleeding.
Unfortunately for all of us what will likely solve the problem is a reverse split and another offering
Yes I would
I would also like to know the ownership of those companies and their affiliations with each other
You’re my boy jack providing such great information.
What can you say about the shorts - making money by trying to destroy those trying to benefit society.
Jack
Enough of the bs. There is plenty wrong with the company, but it is highly highly unlikely Odidi would be creating a company in China apart from ipci. He has fiduciary obligations to the company. Such a move would open him up to serious personal liability.
Good info numbers. You always have very thorough analysis
Still troubled by the may 2017 date. The new company should have been disclosed if an affiliate of intelli.
Seems like there is a good deal of missing or incomplete info. I find it hard to believe this would have got by the 10q disclosures.
He is not just the ceo. He has a controlling interest of shares. Disclosure requirements are in place to prevent these sort of things.
Because it is an affiliated transaction it is required to be disclosed
If there are secret arrangement there are likely sec violations
We need to know what is going on
This should have been addressed by management publicly last night.
Whether smart Pharma is owned by Odidi or intelli it is an affiliate of intelli as the controlling parties are related.
If it was set up in may it should have been disclosed by intelli.
Intelli needs to address this issue ASAP.
I thought they indicated they were doing/did the 40 mg be studies. We should ask patient after we hopefully get an update on this
Any idea how the numbers may shake out compared to us.
Good point.
On focalin they only own rights on 15 and 30.
Not sure if they ever did the testing on the 40 required for approval of the other strengths. We never were updated on that.
Mopar
Could you elaborate on your positive impressions from the meeting
With such pathetic sales number hard to see what could be positively forthcoming
Did they say anything about lack of funds
Did they say anything about future raises
Did they talk of cutting expenses
Expectations about marketing other generics
Anything about podras
Did they mention what they do all day to account for the 12m annual burn
Thanks in adcance
Btw
Thank you Fred.
Wow. Unreal
Have to agree with wm. Earnings will be low 1m.
Hard to see what good news could be upcoming to change things.
Fred or Fabius
Any updates on seroquel and focalin sales numbers
Thanks for your efforts
This is really interesting. I remember the guy on stocktwits saying all he cared about was keeping the price below a certain level until end of the year. Sounded like someone was paying him to keep the price low.
One thing has been clear short action has foretold price action
The deck is stacked in their favor
Agreed on the increased split. If I remember correctly it was double.
We need more clarity on the numbers for sure
I’m not tracking the long term contracts issue
If sales are locked up under long term contracts how did the other may approved generics break into them. Mnks sales are well below the other may approved generics
Based on Bloomberg I question if focalin will hit 1m
The numbers don’t make sense. You say seroquel are high. It looks like focalin may be low.
I’m basing my estimate on extrapolating last quarters numbers based on the progression shown by Bloomberg.
Who knows.
Did ipci give you any insight?
Around 2m - maybe a bit more.
Each accounting for about half
Seroqel rev likely to be 4 tumes aeroquel rev for 3rd quarter. Question is what was 3rd quarter seroquel rev
If the Bloomberg numbers are high how do you figure 1m for focalin
I assume that was from ipci. Did they say anything about why sales are so low and how that might change in the future
Under numbers theory the par numbers are roughly 80m retail per year. Par would then get 15% of that or 12m. At 5% ipci would be getting 600K a year.
Are the focalin and seriquel numbers not from the same Bloomberg source?
I wasn’t real clear. I was referring to the focalin split.
What did you recently learn
If the focalin and seroquel numbers are being pulled from the same Bloomberg spot either there is a disconnect or ipci is getting a much larger percentage cut than any us have speculated
If those numbers are retail and price to supplier is that substantially reduced hard to see how ipci is getting the quarterly return on less than a 10% split
Impact
Did he mention anything about managing the budget and future raises
Did he go through the questions
Did he discuss timing for trials rexista and or podras
Did they say anything about podras studies or where they stand with money and future trials